Halozyme Signs a Collaboration and License Agreement with Chugai for Enhanze Drug-Delivery Technology
Shots:
- Halozyme to receive $25M up front & is also eligible to receive an additional fee of $160M upon the achievement of development, regulatory & sales-based milestones along with royalties on sales of commercialized therapies using Enhanze technology
- Chugai gets the license to use Halozyme's Enhanze drug delivery technology which was based on its patented rHuPH20 for an undisclosed target. Additionally, the new collaboration will expand the no. of Wave of 5 potential launch programs
- Additionally, Chugai plans to investigate the potential use of Enhanze. The collaborations cover 60+ therapeutic targets and include five commercialized products
Ref: Halozyme | Image: Halozyme
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
